Naveen Pemmaraju

145PUBLICATIONS
316CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsHaematological tumoursGene and molecular therapyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (145)

|Aug 13, 2026
Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

|Jul 07, 2026
Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

|Jul 06, 2026
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

|Jun 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

|May 06, 2026
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

|Apr 29, 2026
Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: a real-world study.

Pageof 25

Frequent Collaborators

81 joint publications

Navel G Daver

75 joint publications

Tapan M Kadia

72 joint publications

Courtney DiNardo

68 joint publications

Hagop M Kantarjian